Caplin Point Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Caplin Point Laboratories announced that the Company's wholly owned Subsidiary Caplin Point Far East, Hong Kong, had executed Share Purchase Agreement dated 03 June 2025 for acquiring the entire stake in Triwin Pharma S.A DE C.V, a Mexican Company. The target company is engaged in marketing and distribution of pharmaceutical products.

The acquisition was a strategic decision, as it provides a local partner in Mexico?enabling participation in government tenders and also supporting the establishment of a stock-and-sale model, in line with our successful strategy in other LATAM markets.

Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024.

For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Caplin Point Laboratories has fixed 30 May 2025 as record date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.

Powered by Capital Market - Live News

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News